公司概述
Picard Medical, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it engages in the comprehensive design, manufacturing, production, supply, marketing, and sale of specialized medical device products. The company's primary offering includes the SynCardia TAH, an artificial heart engineered to function as a replacement for a failed human heart in patients with severe cardiac conditions. This entity maintains a relatively modest operational scale, employing 75 individuals to support its product development and distribution channels. With a market capitalization of $67.86M and annual revenue of $4.77M, the company occupies a niche position in the market, indicating a small-cap profile typical of specialized medical device manufacturers that are still establishing significant revenue streams relative to their book value.
财务健康
The company reported a revenue of $4.77M over the trailing twelve months, yet this revenue generated a net income of $-32,220,000, while the EBITDA stood at $-13,661,000. The substantial disparity between the $4.77M revenue and the -$32.22M net income reveals a highly leveraged cost structure where operating expenses significantly exceed total revenue, resulting in an operating margin of -293.8%. This negative profit picture is further reflected in the gross margin of -10.0% and a profit margin of 0.0%, indicating that the company is currently burning cash rather than generating profit on its core sales. Free cash flow for the period was -$10,742,875, which signifies a lack of financial flexibility as the company must rely on external capital or existing cash reserves to fund operations. On the liquidity front, the company holds $2.81M in cash against $616,000 in debt, creating a conservative cash position relative to liabilities, although the debt-to-equity ratio of 7.73 suggests high leverage. The current ratio of 2.16 indicates that the company possesses more than double the current assets required to cover its short-term obligations, pointing to adequate short-term liquidity despite the overall profitability challenges. Return on Equity is listed as N/A due to the negative equity position, while the return on assets stands at -67.3%, revealing that management is currently destroying value rather than generating returns on the asset base employed.
估值评估
The P/E Ratio (TTM) and Forward P/E are both N/A, which implies that traditional earnings-based valuation metrics are inapplicable given the company's negative net income and the absence of expected earnings growth in the near term. Instead, valuation relies on alternative metrics, with the price-to-book ratio standing at 8.53, suggesting that the market values the company at a significant premium of over eight times its book value. The price-to-sales ratio is 14.24, while the EV/EBITDA is -4.81, indicating that the market is pricing in substantial future growth expectations despite the current lack of profitability and negative cash generation. The stock has exhibited extreme volatility, trading between a 52-week high of $13.68 and a 52-week low of $0.92. Without a specific current price provided in the facts to calculate the exact percentage deviation, the wide range highlights the speculative nature of the asset, as the security has recovered from a low of $0.92 to approach the high of $13.68 over the last year. The Beta is listed as N/A, meaning volatility data relative to the broader market is not available or calculable from the provided figures, making it difficult to assess systematic risk without historical market correlation data.
Growth & Income
Revenue growth over the year-over-year period is 34.7%, while earnings growth is N/A due to the negative net income position. The fact that earnings growth is not applicable while revenue is growing rapidly implies that the company is in an expansion phase where top-line sales are increasing faster than the bottom line, which is common for pre-profitability medical device firms scaling up production. As the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it retains all earnings to reinvest into research, development, and manufacturing capacity rather than distributing income to shareholders. The overall growth and income profile is characterized by aggressive top-line expansion of 34.7% revenue growth combined with a complete absence of dividend income, reflecting a high-risk, high-potential-growth strategy typical of small-cap medical device innovators.